|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Interleukin-1β, Interleukin-1 receptor antagonist, Interleukin-6, Interleukin-10, and Tumor Necrosis Factor-α Levels in CSF and Serum in Relation to the Clinical Diversity of Parkinson’s Diseaseстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 2 мая 2018 г.
- Авторы: Karpenko M.N., Vasilishina A.A., Gromova E.A., Muruzheva Z.M., Bernadotte A.
- Журнал: Cellular Immunology
- Том: 2
- Номер: 2
- Год издания: 2018
- Издательство: Academic Press
- Местоположение издательства: United States
- Первая страница: 1
- Последняя страница: 18
- DOI: 10.1016/j.cellimm.2018.02.011
- Аннотация: Abstract: Several parameters representing the clinical diversity of Parkinson's disease (PD), including severity, phenotypes, cognitive decline, anxiety and depression were analyzed to examine the link with interleukin-1β (IL-1β), the interleukin-1 receptor antagonist (IL-1RA), IL-6, IL-10, and tumor necrosis factor-α (TNFα) and also to determine the relationship between levels of these factors in serum and cerebrospinal fluid (CSF). Significantly elevated serum IL-1β and IL-6 and reduced IL- 1RA levels were found in the PD group. In CSF and serum, inflammatory factors behaved differently, with increased CSF TNFα indicating rapid PD progression, while IL-1β was found to be increased in serum. A low level of IL-6 was associated with a longer duration of PD. Anxiety, depression, non-tremor phenotype and late-onset PD correlated with a high serum level of IL-10. The serum TNFα level was lower in PD patients with mild cognitive impairment compared to controls. Serum IL-1β, IL-6 and IL-10 levels correlated with these markers in CSF.
- Добавил в систему: Бернадотт Александра